Head to Head Comparison: Histogenics (HSGX) & Neos Therapeutics (NEOS)

Histogenics (NASDAQ: HSGX) and Neos Therapeutics (NASDAQ:NEOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Valuation & Earnings

This table compares Histogenics and Neos Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Histogenics N/A N/A -$16.20 million ($1.38) -2.07
Neos Therapeutics $9.15 million 28.52 -$83.33 million ($3.42) -2.63

Histogenics has higher earnings, but lower revenue than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than Histogenics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

50.5% of Histogenics shares are owned by institutional investors. Comparatively, 49.3% of Neos Therapeutics shares are owned by institutional investors. 23.8% of Histogenics shares are owned by insiders. Comparatively, 5.2% of Neos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Histogenics and Neos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Histogenics N/A -658.91% -106.38%
Neos Therapeutics -339.52% -551.26% -68.57%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Histogenics and Neos Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Histogenics 0 0 2 0 3.00
Neos Therapeutics 0 1 4 0 2.80

Histogenics currently has a consensus price target of $4.00, indicating a potential upside of 40.35%. Neos Therapeutics has a consensus price target of $16.20, indicating a potential upside of 80.00%. Given Neos Therapeutics’ higher probable upside, analysts clearly believe Neos Therapeutics is more favorable than Histogenics.

Volatility & Risk

Histogenics has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Neos Therapeutics has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500.


Histogenics beats Neos Therapeutics on 8 of the 13 factors compared between the two stocks.

Histogenics Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply